Table 2.

Treatment-emergent adverse events

	All patients, n = 70
	Grade 1–2	Grade 3	Grade 4	Grade 5
Fatigue	28 (40)	5 (7)	0	0
Dizziness	22 (31)	1 (1)	0	0
Anaemia	12 (17)	10 (14)	0	0
Nausea	20 (29)	0	0	0
Constipation	17 (24)	1 (1)	0	0
Dyspnoea	15 (21)	3 (4)	0	0
Cough	16 (23)	0	0	0
Vomiting	14 (20)	1 (1)	0	0
Diarrhoea	13 (19)	1 (1)	0	0
Decreased appetite	10 (14)	3 (4)	0	0
Oedema peripheral	13 (19)	0	0	0
Myalgia	11 (16)	1 (1)	0	0
Arthralgia	10 (14)	1 (1)	0	0
Pyrexia	11 (16)	0	0	0
Aspartate aminotransferase increased	6 (9)	4 (6)	0	0
Muscular weakness	10 (14)	0	0	0
Abdominal pain	7 (10)	2 (3)	0	0
Dysgeusia	9 (13)	0	0	0
Back pain	8 (11)	0	0	0
Hypertension	6 (9)	2 (3)	0	0
Blood alkaline phosphatase increased	6 (9)	1 (1)	0	0
Gait disturbance	6 (9)	1 (1)	0	0
Hypoalbuminaemia	6 (9)	1 (1)	0	0
Insomnia	7 (10)	0	0	0
Memory impairment	7 (10)	0	0	0
Paraesthesia	7 (10)	0	0	0

Data are n (%). Table shows adverse events occurring in ≥10% of patients at any grade.